Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy

by Lylia Ouboussad, Agata N. Burska, Andrew Melville, Maya H. Buch, Maya H. Buch
Published 2019-03-01

Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations

by Sarah Horton, Maya H Buch, Paul Emery
Published 2010-08-01

Mixed results with baricitinib in biological-resistant adult-onset Still’s disease and undifferentiated systemic autoinflammatory disease

by Maya H Buch, Mark Kacar, John Fitton, Andrew K Gough
Published 2020-08-01

Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?

by Vasco C. Romão, Edward M. Vital, João Eurico Fonseca, Maya H. Buch
Published 2017-10-01

Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: a scoping review protocol

by Maya H Buch, John D Pauling, Michael Hughes, Alain Lescoat, David Roofeh, Whitney Townsend, Robert D Sandler, François Zimmermann
Published 2021-03-01

Using cardiovascular magnetic resonance to define mechanisms of comorbidity and to measure the effect of biological therapy: the CADERA observational study

by Sven Plein, Bara Erhayiem, Graham Fent, Jacqueline Andrews, John Greenwood, Paul Baxter, Elizabeth M Hensor, Sue Pavitt, Maya H Buch
Published 2021-03-01

Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheuma...

by Janusz Jaworski, Marco Matucci-Cerinic, Hendrik Schulze-Koops, Maya H. Buch, Eugeniusz J. Kucharz, Yannick Allanore, Arthur Kavanaugh, Philip Young, Goran Babic
Published 2019-05-01

Carotid artery volumetric measures associate with clinical ten-year cardiovascular (CV) risk scores and individual traditional CV risk factors in rheumatoid arthritis; a carotid-MR...

by Lesley-Anne Bissell, Bara Erhayiem, Graham Fent, Elizabeth M. A. Hensor, Agata Burska, Helena Donica, Sven Plein, Maya H. Buch, John P. Greenwood, Jacqueline Andrews
Published 2018-12-01

Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT

by Sarah Brown, Colin C Everett, Kamran Naraghi, Claire Davies, Bryony Dawkins, Claire Hulme, Christopher McCabe, Sue Pavitt, Paul Emery, Linda Sharples, Maya H Buch
Published 2018-06-01

Muscle Damage in Systemic Sclerosis and CXCL10: The Potential Therapeutic Role of PDE5 Inhibition

by Clarissa Corinaldesi, Rebecca L. Ross, Giuseppina Abignano, Cristina Antinozzi, Francesco Marampon, Luigi di Luigi, Maya H Buch, Valeria Riccieri, Andrea Lenzi, Clara Crescioli, Francesco Del Galdo
Published 2021-03-01

The PREdictor of MAlnutrition in Systemic Sclerosis (PREMASS) Score: A Combined Index to Predict 12 Months Onset of Malnutrition in Systemic Sclerosis

by Gianluca Bagnato, Gianluca Bagnato, Erika Pigatto, Alessandra Bitto, Gabriele Pizzino, Natasha Irrera, Giuseppina Abignano, Giuseppina Abignano, Antonino Ferrera, Davide Sciortino, Michelle Wilson, Francesco Squadrito, Maya H. Buch, Paul Emery, Elisabetta Zanatta, Sebastiano Gangemi, Antonino Saitta, Franco Cozzi, William Neal Roberts, Francesco Del Galdo
Published 2021-03-01